AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM)
January 03, 2022 12:10 ET
|
AB Science
PRESS RELEASE AB SCIENCE HAS BEEN GRANTED AUTHORIZATION TO INITIATE CONFIRMATORY PHASE III TRIAL OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS BY THE FRENCH HEALTH AUTHORITY (ANSM) Paris,...
AB Science reçoit l’autorisation de la FDA pour initier le programme de développement clinique du masitinib dans le syndrome d’activation des mastocytes (MCAS)
October 04, 2021 12:10 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT L'AUTORISATION DE LA FOOD AND DRUG ADMINISTRATION (FDA) AMÉRICAINE POUR INITIER LE PROGRAMME DE DÉVELOPPEMENT CLINIQUE DU MASITINIB DANS LE SYNDROME...
AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)
October 04, 2021 12:10 ET
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO START CLINICAL DEVELOPMENT PROGRAM OF MASITINIB IN MAST CELL ACTIVATION SYNDROME (MCAS) MCAS IS A...
Global Allergy Treatment Markets Report 2021-2026: Allergy Therapeutics and ALK-Abello Dominates the Immunotherapy Segment
September 21, 2021 05:53 ET
|
Research and Markets
Dublin, Sept. 21, 2021 (GLOBE NEWSWIRE) -- The "Allergy Treatment Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The allergy treatment...
AB Science annonce avoir reçu de nouvelles autorisations portant sur la reprise des inclusions de ses études de phase 3 du masitinib
September 14, 2021 12:01 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE AVOIR RECU DE NOUVELLES AUTORISATIONS PORTANT SUR LA REPRISE DES INCLUSIONS DE SES ETUDES DE PHASE 3 DU MASITINIB, CONFIRMANT UNE REPRISE GLOBALE DE CES ETUDES...
AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib
September 14, 2021 12:01 ET
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT IT HAS RECEIVED NEW AUTHORIZATIONS TO RESUME PATIENT ENROLLMENT IN ITS PHASE 3 STUDIES OF MASITINIB, CONFIRMING A GLOBAL RESUMPTION OF THESE STUDIES Paris,...
AB Science annonce qu'une publication indépendante confirme le rôle du masitinib comme thérapie potentielle dans les troubles neurodégénératifs, y compris la maladie d'Alzheimer
March 08, 2021 02:02 ET
|
AB Science
COMMUNIQUE DE PRESSE UNE NOUVELLE PUBLICATION INDÉPENDANTE DANS LA REVUE INTERNATIONALE...
AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in neurodegenerative disorders including Alzheimer's Disease
March 08, 2021 02:02 ET
|
AB Science
PRESS RELEASE NEW INDEPENDENT PUBLICATION IN THE INTERNATIONAL JOURNAL OF...
AB Science annonce qu'une nouvelle publication indépendante confirme le rôle du masitinib comme thérapie potentielle dans le cancer du pancréas
February 23, 2021 02:02 ET
|
AB Science
COMMUNIQUE DE PRESSE UNE NOUVELLE PUBLICATION INDÉPENDANTE DANS LA REVUE...
AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer
February 23, 2021 02:02 ET
|
AB Science
PRESS RELEASE NEW INDEPENDENT PUBLICATION IN THE PEER-REVIEWED SCIENTIFIC...